Sara Tariq Alrashood

Work Experience

• 2019-Present: Professor of Drug Designing - King Saud University, Riyadh, Saudi Arabia.
• 2017-2019: Associate Professor of Drug Designing - King Saud University, Riyadh, Saudi Arabia.
• 2012-2017: Assistant Professor of Drug Designing - King Saud University, Riyadh, Saudi Arabia.
• 2006-2012: Lecturer - King Saud University, Riyadh, Saudi Arabia.
• 2001-2006: Teaching Assistant - King Saud University, Riyadh, Saudi Arabia.

Research & Development

• 2019-Present: KSU RSP Research Fund.
• 2018-Present: KSU Research Group Fund.
• 2018-Present: KACST Fund – NNI Research Group.
• 2018-Present: KACST Fund – KSU Research Group.
• 2018-Present: KSU Research Group – Deanship of Scientific Research.
• 2017-Present: King Khaled Eye Specialist Hospital (KKESH )– Research Center.
• 2016-Present: NNIH - Research Center.
• 2012: Raed Fund – Postdoctoral Research.

Additional Research Position

• 2013: Research Fellow in Neuro-Drug-Designing from Harvard University.
• 2009: Research fellow in Drug Discovery and molecular Designing from UCLA.
• 2007: Research Fellow in Drug Designing and Drug modeling from Stanford University.

Education and Training

• 2018: Diploma in vuca leadership, Cornell University, Ithaca, United States.
• 2011: Ph.D. In drug designing from pharmacy college, Pharmaceutical Chemistry Department, King Saud University, Riyadh, Saudi Arabia.
• 2016: Higher diploma in molecular modeling engineering, University of San Francisco, United States.
• 2015: Higher diploma in drug discovery and drug toxicology, Cambridge University, United Kingdom.
• 2005: M.Sc. In Medicinal Chemistry, drug designing from pharmacy College, Pharmaceutical Chemistry Department, King Saud University, Riyadh, Saudi Arabia.
• 2004: Higher Diploma in Drug Discovery and Drug Toxicology, Cambridge University, United Kingdom.
• 2002: B.sc. In Pharmaceutical Sciences (High Honor), King Saud University, Riyadh, Saudi Arabia.

Research Interests

• My Research Interests focus on the discovery and development of novel drugs and biological probes. To achieve these objectives I evaluate at a molecular level small molecules (SMs) including privileged structural motives and synthetic scaffolds with a prominent interest in those that can affect cell division. The resulting SM libraries, available from long and short-term external collaborations, are screened in our Drug Discovery implementation, which allows interrogating relevant biological activity.
• Have more than 50 Published Papers in the field and in in multiciliary with Finance and Public heath. https://scholar.google.com/citations?user=5tlPnuoAAAAJ&hl=en